Literature DB >> 3237686

Improved antigenicity of the HIV env protein by cleavage site removal.

M P Kieny1, R Lathe, Y Rivière, K Dott, D Schmitt, M Girard, L Montagnier, J Lecocq.   

Abstract

The HIV env glycoprotein mediates virus infection and cell fusion through an interaction with the CD4 molecule present at the surface of T4+ lymphocytes. Although env presents a major antigenic target, vaccinia recombinants expressing env elicit low titres of anti-env antibody (Kieny et al., Bio/Technology, 4, 790-795, 1986). To delimit the functional domains of env and to improve the immunogenicity of the vaccinia recombinants we constructed variants expressing env proteins in which the site permitting cleavage of the gp160 precursor to yield gp120 and gp41 was removed, the gp120 and gp41 moieties separated or in which the signal sequence and hydrophobic domains were replaced by equivalents from rabies virus G. Analysis of variants revealed that the gp120 moiety is alone capable of interacting with CD4 and of provoking aggregation of T4+ lymphocytes, whereas cell-associated gp41 liberated by gp160 cleavage was essential for cell fusion. The identity of the signal and transmembrane zones however appeared unimportant. Although removal of the consensus sequence permitting cleavage of gp160 prevented syncytium formation but not aggregation of T4+ lymphocytes, significant cleavage continued to take place. Removal of a second potential cleavage site blocked gp160 cleavage. The live viruses were examined for immunogenicity: recombinant 1139 which lacks both putative cleavage sites was found to elicit a 10-fold higher antibody response in experimental animals than the parental recombinant.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3237686     DOI: 10.1093/protein/2.3.219

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  37 in total

1.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Simple assay to screen for inhibitors of interaction between the human immunodeficiency virus envelope glycoprotein and its cellular receptor, CD4.

Authors:  V Chams; T Idziorek; P J Maddon; D Klatzmann
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.

Authors:  P L Earl; S Koenig; B Moss
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

4.  Effects of mutations in hyperconserved regions of the extracellular glycoprotein of human immunodeficiency virus type 1 on receptor binding.

Authors:  A Cordonnier; Y Rivière; L Montagnier; M Emerman
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

5.  From vaccines to global health to vaccines.

Authors:  Marie-Paule Kieny
Journal:  Hum Vaccin Immunother       Date:  2018-09-14       Impact factor: 3.452

6.  Aminosugar derivatives as potential anti-human immunodeficiency virus agents.

Authors:  A Karpas; G W Fleet; R A Dwek; S Petursson; S K Namgoong; N G Ramsden; G S Jacob; T W Rademacher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites.

Authors:  A Pinter; W J Honnen; S A Tilley
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

8.  A furin-defective cell line is able to process correctly the gp160 of human immunodeficiency virus type 1.

Authors:  Y Ohnishi; T Shioda; K Nakayama; S Iwata; B Gotoh; M Hamaguchi; Y Nagai
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  Reduced cell surface expression of processed human immunodeficiency virus type 1 envelope glycoprotein in the presence of Nef.

Authors:  O Schwartz; Y Rivière; J M Heard; O Danos
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells.

Authors:  J F Mayaux; A Bousseau; R Pauwels; T Huet; Y Hénin; N Dereu; M Evers; F Soler; C Poujade; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.